{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T05:21:51Z","timestamp":1732684911639,"version":"3.28.2"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"DOI":"10.1186\/s13104-024-07004-2","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T10:44:45Z","timestamp":1732617885000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of anticoagulation options for non-valvular atrial fibrillation in Iran"],"prefix":"10.1186","volume":"17","author":[{"given":"Satar","family":"Rezaei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Bavandpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadreza","family":"Mobinizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajabali","family":"Daroudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"issue":"12","key":"7004_CR1","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.amjmed.2016.06.045","volume":"129","author":"L Fauchier","year":"2016","unstructured":"Fauchier L, Villejoubert O, Clementy N, Bernard A, Pierre B, Angoulvant D, et al. Causes of death and influencing factors in patients with atrial fibrillation. Am J Med. 2016;129(12):1278\u201387.","journal-title":"Am J Med"},{"issue":"12","key":"7004_CR2","doi-asserted-by":"publisher","first-page":"e0209687","DOI":"10.1371\/journal.pone.0209687","volume":"13","author":"E Lee","year":"2018","unstructured":"Lee E, Choi E-K, Han K-D, Lee H, Choe W-S, Lee S-R, et al. Mortality and causes of death in patients with atrial fibrillation: a nationwide population-based study. PLoS ONE. 2018;13(12):e0209687.","journal-title":"PLoS ONE"},{"issue":"3","key":"7004_CR3","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1136\/hrt.2002.008748","volume":"90","author":"S Stewart","year":"2004","unstructured":"Stewart S, Murphy N, Walker A, McGuire A, McMurray J. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart. 2004;90(3):286\u201392.","journal-title":"Heart"},{"issue":"3","key":"7004_CR4","first-page":"313","volume":"4","author":"MH Kim","year":"2011","unstructured":"Kim MH, Johnston SS, Chu B-C, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circulation: Cardiovasc Qual Outcomes. 2011;4(3):313\u201320.","journal-title":"Circulation: Cardiovasc Qual Outcomes"},{"issue":"6","key":"7004_CR5","first-page":"937","volume":"19","author":"X Li","year":"2017","unstructured":"Li X, Tse VC, Au-Doung LW, Wong ICK, Chan EW. The impact of ischaemic stroke on atrial fibrillation-related healthcare cost: a systematic review. Europace. 2017;19(6):937\u201347.","journal-title":"Europace"},{"issue":"3","key":"7004_CR6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.5414\/CP202651","volume":"55","author":"N Masbah","year":"2017","unstructured":"Masbah N, Macleod MJ. The cost savings of newer oral anticoagulants in atrial fibrillation-related stroke prevention. Int J Clin Pharmacol Ther. 2017;55(3):220\u201330.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"7004_CR7","doi-asserted-by":"publisher","first-page":"20264","DOI":"10.1038\/s41598-024-71296-4","volume":"14","author":"H Soleimani","year":"2024","unstructured":"Soleimani H, Tavakoli K, Nasrollahizadeh A, Azadnajafabad S, Mashayekhi M, Ebrahimi P, et al. Estimating the burden of atrial fibrillation and atrial flutter with projection to 2050 in Iran. Sci Rep. 2024;14(1):20264.","journal-title":"Sci Rep"},{"key":"7004_CR8","doi-asserted-by":"crossref","unstructured":"Mohammadi 8S, Rezapur A, Azari S et al. Economic Burden of Atrial Fibrillation Disease in Iran, 15 January 2024, PREPRINT (Version 1) available at Research Square [https:\/\/doi.org\/10.21203\/rs3rs-3848585\/v1]","DOI":"10.21203\/rs.3.rs-3848585\/v1"},{"issue":"2","key":"7004_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.thromres.2014.05.027","volume":"134","author":"T Lanitis","year":"2014","unstructured":"Lanitis T, Kongnakorn T, Jacobson L, De Geer A. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation. Thromb Res. 2014;134(2):278\u201387.","journal-title":"Thromb Res"},{"issue":"1","key":"7004_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/AC.67.1.2146567","volume":"67","author":"G Ntaios","year":"2012","unstructured":"Ntaios G, Manios E, Synetou M, Savvari P, Vemmou A, Koromboki E, et al. Prevalence of atrial fibrillation in Greece: the Arcadia rural study on atrial fibrillation. Acta Cardiol. 2012;67(1):65\u20139.","journal-title":"Acta Cardiol"},{"issue":"8","key":"7004_CR11","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a global burden of Disease 2010 study. Circulation. 2014;129(8):837\u201347.","journal-title":"Circulation"},{"issue":"1\u20132","key":"7004_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.26719\/2004.10.1-2.147","volume":"10","author":"F Habibzadeh","year":"2004","unstructured":"Habibzadeh F, Yadollahie M, Roshanipoor M, Haghighi AB. Prevalence of atrial fibrillation in a primary health care centre in Fars Province, Islamic Republic of Iran. East Mediterr Health J. 2004;10(1\u20132):147\u201351.","journal-title":"East Mediterr Health J"},{"issue":"16","key":"7004_CR13","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330\u201393.","journal-title":"Eur Heart J"},{"issue":"24","key":"7004_CR14","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/j.jacc.2018.04.013","volume":"71","author":"M Alkhouli","year":"2018","unstructured":"Alkhouli M, Noseworthy PA, Rihal CS, Holmes DR. Stroke prevention in nonvalvular atrial fibrillation: a stakeholder perspective. J Am Coll Cardiol. 2018;71(24):2790\u2013801.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"7004_CR15","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392.","journal-title":"N Engl J Med"},{"key":"7004_CR16","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-L\u00f3pez JA, Sterne JA, Thom HH, Higgins JP, Hingorani AD, Okoli GN et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359.","DOI":"10.1136\/bmj.j5058"},{"key":"7004_CR17","doi-asserted-by":"crossref","unstructured":"Jaberi N, Kavosi Z, Hooshmandi E, Moradi N, Keshavarz K, Borhani-Haghighi A. The study of cost-effectiveness of rivaroxaban versus warfarin in patients with atrial fibrillation who developed ischemic stroke. Stroke Research and Treatment. 2021;2021.","DOI":"10.1155\/2021\/5534873"},{"issue":"8","key":"7004_CR18","doi-asserted-by":"publisher","first-page":"e14313","DOI":"10.1111\/ijcp.14313","volume":"75","author":"M Heidarali","year":"2021","unstructured":"Heidarali M, Bakhshandeh H, Golpira R, Fazelifar A, Alizadeh-Diz A, Emkanjoo Z, et al. A prospective survey of atrial fibrillation management in Iran: baseline results of the Iranian Registry of Atrial Fibrillation (IRAF). Int J Clin Pract. 2021;75(8):e14313.","journal-title":"Int J Clin Pract"},{"issue":"28","key":"7004_CR19","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1093\/eurheartj\/ehu006","volume":"35","author":"P Dorian","year":"2014","unstructured":"Dorian P, Kongnakorn T, Phatak H, Rublee DA, Kuznik A, Lanitis T, et al. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. Eur Heart J. 2014;35(28):1897\u2013906.","journal-title":"Eur Heart J"},{"issue":"31","key":"7004_CR20","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1093\/eurheartj\/eht135","volume":"34","author":"SM Al-Khatib","year":"2013","unstructured":"Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D, et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J. 2013;34(31):2464\u201371.","journal-title":"Eur Heart J"},{"issue":"9","key":"7004_CR21","doi-asserted-by":"publisher","first-page":"e0222658","DOI":"10.1371\/journal.pone.0222658","volume":"14","author":"LA de Jong","year":"2019","unstructured":"de Jong LA, Groeneveld J, Stevanovic J, Rila H, Tieleman RG, Huisman MV, et al. Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings. PLoS ONE. 2019;14(9):e0222658.","journal-title":"PLoS ONE"},{"key":"7004_CR22","unstructured":"World Health Organization. (2023). Iran Life Tables. Global Health Observatory (GHO) data. Retrieved from https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/gho-ghe-life-tables-by-country"},{"key":"7004_CR23","doi-asserted-by":"crossref","unstructured":"Almutairi AR, Zhou L, Gellad WF, Lee JK, Slack MK, Martin JR, Lo-Ciganic W-H. Effectiveness and safety of non\u2013vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta-analyses. Clinical therapeutics. 2017;39(7):1456-78. e36.","DOI":"10.1016\/j.clinthera.2017.05.358"},{"issue":"13","key":"7004_CR24","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.3390\/jcm11133788","volume":"11","author":"BJ Buckley","year":"2022","unstructured":"Buckley BJ, Lane DA, Calvert P, Zhang J, Gent D, Mullins CD, et al. Effectiveness and safety of apixaban in over 3.9 million people with atrial fibrillation: a systematic review and meta-analysis. J Clin Med. 2022;11(13):3788.","journal-title":"J Clin Med"},{"issue":"12","key":"7004_CR25","doi-asserted-by":"publisher","first-page":"873","DOI":"10.2459\/JCM.0000000000000206","volume":"15","author":"W Fu","year":"2014","unstructured":"Fu W, Guo H, Guo J, Lin K, Wang H, Zhang Y, et al. Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis. J Cardiovasc Med (Hagerstown Md). 2014;15(12):873.","journal-title":"J Cardiovasc Med (Hagerstown Md)"},{"key":"7004_CR26","unstructured":"https:\/\/irc.fda.gov.ir\/nfi [accessed 25 September 2022)."},{"issue":"12","key":"7004_CR27","doi-asserted-by":"publisher","first-page":"e067573","DOI":"10.1136\/bmjopen-2022-067573","volume":"12","author":"Z Kazemi","year":"2022","unstructured":"Kazemi Z, Emamgholipour Sefiddashti S, Daroudi R, Ghorbani A, Yunesian M, Hassanvand MS, Shahali Z. Estimation and predictors of direct hospitalisation expenses and in-hospital mortality for patients who had a stroke in a low-middle income country: evidence from a nationwide cross-sectional study in Iranian hospitals. BMJ Open. 2022;12(12):e067573.","journal-title":"BMJ Open"},{"issue":"4","key":"7004_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.5144\/0256-4947.2019.265","volume":"39","author":"AS Hersi","year":"2019","unstructured":"Hersi AS, Osenenko KM, Kherraf SA, Aziz AA, Sambrook RJ. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia. Ann Saudi Med. 2019;39(4):265\u201378.","journal-title":"Ann Saudi Med"},{"issue":"2","key":"7004_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40256-016-0204-1","volume":"17","author":"K Athanasakis","year":"2017","unstructured":"Athanasakis K, Boubouchairopoulou N, Karampli E, Tarantilis F, Savvari P, Bilitou A, Kyriopoulos J. Cost effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in patients with Atrial Fibrillation: a Greek perspective. Am J Cardiovasc Drugs. 2017;17(2):123\u201333.","journal-title":"Am J Cardiovasc Drugs"},{"key":"7004_CR30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s41669-019-00186-7","volume":"4","author":"I Oyag\u00fcez","year":"2020","unstructured":"Oyag\u00fcez I, Su\u00e1rez C, L\u00f3pez-Send\u00f3n JL, Gonz\u00e1lez-Juanatey JR, de Andr\u00e9s-Nogales F, Su\u00e1rez J, et al. Cost-effectiveness analysis of apixaban versus edoxaban in patients with atrial fibrillation for stroke prevention. PharmacoEconomics-Open. 2020;4:485\u201397.","journal-title":"PharmacoEconomics-Open"},{"issue":"12","key":"7004_CR31","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/hec.901","volume":"13","author":"G Richardson","year":"2004","unstructured":"Richardson G, Manca A. Calculation of quality adjusted life years in the published literature: a review of methodology and transparency. Health Econ. 2004;13(12):1203\u201310.","journal-title":"Health Econ"},{"issue":"5","key":"7004_CR32","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/heapol\/czl018","volume":"21","author":"F Sassi","year":"2006","unstructured":"Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plann. 2006;21(5):402\u20138.","journal-title":"Health Policy Plann"},{"issue":"9","key":"7004_CR33","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s10198-022-01445-x","volume":"23","author":"E Khorasani","year":"2022","unstructured":"Khorasani E, Davari M, Kebriaeezadeh A, Fatemi F, Akbari Sari A, Varahrami V. A comprehensive review of official discount rates in guidelines of health economic evaluations over time: the trends and roots. Eur J Health Econ. 2022;23(9):1577\u201390.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"7004_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12962-020-00256-2","volume":"19","author":"R Hashempour","year":"2021","unstructured":"Hashempour R, Raei B, Safaei Lari M, Abolhasanbeigi Gallezan N, AkbariSari A. QALY League table of Iran: a practical method for better resource allocation. Cost Eff Resource Allocation. 2021;19(1):3.","journal-title":"Cost Eff Resource Allocation"},{"key":"7004_CR35","unstructured":"https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CN?locations=IR"},{"key":"7004_CR36","unstructured":"https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD?locations=IR"},{"issue":"1","key":"7004_CR37","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1017\/S0266462321001732","volume":"38","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Int J Technol Assess Health Care. 2022;38(1):e13.","journal-title":"Int J Technol Assess Health Care"},{"key":"7004_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.vhri.2023.02.003","volume":"36","author":"K Peng","year":"2023","unstructured":"Peng K, Li Y, Chan EW, Wong IC, Li X. Cost-effectiveness of direct oral anticoagulants in patients with Nonvalvular Atrial Fibrillation in Hong Kong. Value Health Reg Issues. 2023;36:51\u20137.","journal-title":"Value Health Reg Issues"},{"issue":"11","key":"7004_CR39","doi-asserted-by":"publisher","first-page":"e0259251","DOI":"10.1371\/journal.pone.0259251","volume":"16","author":"S Rivolo","year":"2021","unstructured":"Rivolo S, Di Fusco M, Polanco C, Kang A, Dhanda D, Savone M, et al. Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain. PLoS ONE. 2021;16(11):e0259251.","journal-title":"PLoS ONE"},{"issue":"4","key":"7004_CR40","doi-asserted-by":"publisher","first-page":"e62183","DOI":"10.1371\/journal.pone.0062183","volume":"8","author":"BL Limone","year":"2013","unstructured":"Limone BL, Baker WL, Kluger J, Coleman CI. Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLoS ONE. 2013;8(4):e62183.","journal-title":"PLoS ONE"},{"issue":"4","key":"7004_CR41","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jval.2013.01.009","volume":"16","author":"D Coyle","year":"2013","unstructured":"Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S, Wells GA. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health. 2013;16(4):498\u2013506.","journal-title":"Value Health"},{"key":"7004_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40261-013-0144-3","volume":"34","author":"C Rognoni","year":"2014","unstructured":"Rognoni C, Marchetti M, Quaglini S, Liberato NL. Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. Clin Drug Investig. 2014;34:9\u201317.","journal-title":"Clin Drug Investig"},{"key":"7004_CR43","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s40273-020-00960-0","volume":"38","author":"C-Y Wang","year":"2020","unstructured":"Wang C-Y, Pham PN, Thai TN, Brown JD. Updating the cost effectiveness of oral anticoagulants for patients with atrial fibrillation based on varying stroke and bleed risk profiles. PharmacoEconomics. 2020;38:1333\u201343.","journal-title":"PharmacoEconomics"},{"key":"7004_CR44","doi-asserted-by":"publisher","first-page":"004695802210814","DOI":"10.1177\/00469580221081438","volume":"59","author":"M Yanovskiy","year":"2022","unstructured":"Yanovskiy M, Levy ON, Shaki YY, Zigdon A, Socol Y. Cost-effectiveness threshold for Healthcare: justification and quantification. INQUIRY: J Health Care Organ Provis Financing. 2022;59:00469580221081438.","journal-title":"INQUIRY: J Health Care Organ Provis Financing"},{"issue":"2","key":"7004_CR45","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1586\/14737167.8.2.165","volume":"8","author":"SD Grosse","year":"2008","unstructured":"Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165\u201378.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"7004_CR46","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.thromres.2016.10.006","volume":"150","author":"I Hernandez","year":"2017","unstructured":"Hernandez I, Smith KJ, Zhang Y. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. Thromb Res. 2017;150:123\u201330.","journal-title":"Thromb Res"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-024-07004-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-024-07004-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-024-07004-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T11:07:26Z","timestamp":1732619246000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-024-07004-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["7004"],"URL":"https:\/\/doi.org\/10.1186\/s13104-024-07004-2","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"28 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the Research Ethics Committee of the School of Public Health at Tehran University of Medical Sciences (IR.TUMS.SPH.REC.1402.077). The required data were extracted from previous studies on this topic according to the study aims, and consequently, obtaining informed consent was not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"345"}}